Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-148 (Eculizumab Biosimilar) vs Soliris in Healthy Volunteers
NCT04027803Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BCD-148 in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by BIOCAD. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity. Started Sep 2018; status: completed.
02
Drugs
BCD-148
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04027803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027803.